Alana da Cunha Goldstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alana da Cunha Goldstein has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Fernando Araujo-Lima
Laboratory of Environmental Mutagenesis, Department of Biophysics and Biometry, Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, RJ, Brazil
2 shared publications - Israel Felzenszwalb
Laboratory of Environmental Mutagenesis, Department of Biophysics and Biometry, Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, RJ, Brazil
2 shared publications - Alvaro José Romanha
Centro de Pesquisas René Rachou/CPqRR—Fiocruz, Belo Horizonte 30190-009, Brazil
1 shared publication - Andreia da Silva Fernandes
Department of Biophysics and Biometry, Rio de Janeiro State University, Rio de Janeiro, Brazil
1 shared publication - Bárbara Verena Dias Galvão
Department of Biophysics and Biometry, Rio de Janeiro State University, Rio de Janeiro, Brazil
1 shared publication - Cheyene Almeida Celestino Menozzi
Programa de Pós-Graduação em Farmacologia e Química Medicinal—PPGFQM-Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Bloco J, Ilha do Fundão, Rio de Janeiro 21941-902, Brazil
1 shared publication
Latest Publications
- Open Access
Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives
Chagas disease (CD), which is caused by Trypanosoma cruzi and was discovered more than 100 years ago, remains the leading cause of death from parasitic diseases in the Americas. As a curative treatment is only available for the acute phase of CD, the search for new therapeutic options is urgent. In this study, nitroazole and azole compounds were synthesized and underwent molecular modeling, anti-T. cruzi evaluations and nitroreductase enzymatic assays. The compounds were designed as possible inhibitors of ergosterol biosynthesis and/or as substrates of nitroreductase enzymes. The in vitro evaluation against T. cruzi clearly showed that nitrotriazole compounds are significantly more potent than nitroimidazoles and triazoles. When their carbonyls were reduced to hydroxyl groups, the compounds showed a significant increase in activity. In addition, these substances showed potential for action via nitroreductase activation, as the substances were metabolized at higher rates than benznidazole (BZN), a reference drug against CD. Among the compounds, 1-(2,4-difluorophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethanol (8) is the most potent and selective of the series, with an IC50 of 0.39 µM and selectivity index of 3077; compared to BZN, 8 is 4-fold more potent and 2-fold more selective. Moreover, this compound was not mutagenic at any of the concentrations evaluated, exhibited a favorable in silico ADMET profile and showed a low potential for hepatotoxicity, as evidenced by the high values of CC50 in HepG2 cells. Furthermore, compared to BZN, derivative 8 showed a higher rate of conversion by nitroreductase and was metabolized three times more quickly when both compounds were tested at a concentration of 50 µM. The results obtained by the enzymatic evaluation and molecular docking studies suggest that, as planned, nitroazole derivatives may utilize the nitroreductase metabolism pathway as their main mechanism of action against Trypanosoma cruzi. In summary, we have successfully identified and characterized new nitrotriazole analogs, demonstrating their potential as promising candidates for the development of Chagas disease drug candidates that function via nitroreductase activation, are considerably selective and show no mutagenic potential.
Open AccessAnti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives
Chagas disease (CD), which is caused by Trypanosoma cruzi and was discovered more than 100 years ago, remains the leading cause of death from parasitic diseases in the Americas. As a curative treatment is only available for the acute phase of CD, the search for new therapeutic options is urgent. In this study, nitroazole and azole compounds were synthesized and underwent molecular modeling, anti-T. cruzi evaluations and nitroreductase enzymatic assays. The compounds were designed as possible inhibitors of ergosterol biosynthesis and/or as substrates of nitroreductase enzymes. The in vitro evaluation against T. cruzi clearly showed that nitrotriazole compounds are significantly more potent than nitroimidazoles and triazoles. When their carbonyls were reduced to hydroxyl groups, the compounds showed a significant increase in activity. In addition, these substances showed potential for action via nitroreductase activation, as the substances were metabolized at higher rates than benznidazole (BZN), a reference drug against CD. Among the compounds, 1-(2,4-difluorophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethanol (8) is the most potent and selective of the series, with an IC50 of 0.39 µM and selectivity index of 3077; compared to BZN, 8 is 4-fold more potent and 2-fold more selective. Moreover, this compound was not mutagenic at any of the concentrations evaluated, exhibited a favorable in silico ADMET profile and showed a low potential for hepatotoxicity, as evidenced by the high values of CC50 in HepG2 cells. Furthermore, compared to BZN, derivative 8 showed a higher rate of conversion by nitroreductase and was metabolized three times more quickly when both compounds were tested at a concentration of 50 µM. The results obtained by the enzymatic evaluation and molecular docking studies suggest that, as planned, nitroazole derivatives may utilize the nitroreductase metabolism pathway as their main mechanism of action against Trypanosoma cruzi. In summary, we have successfully identified and characterized new nitrotriazole analogs, demonstrating their potential as promising candidates for the development of Chagas disease drug candidates that function via nitroreductase activation, are considerably selective and show no mutagenic potential.
- 19 November 2022
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 885, 503563
In vitro genotoxicity assessment of graphene quantum dots nanoparticles: A metabolism-dependent response
- 19 November 2022
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 885, 503563
In vitro genotoxicity assessment of graphene quantum dots nanoparticles: A metabolism-dependent response